undamentalytics Newsletter

Hedge fund

Kynam Capital Management, LP

13F for June 30, 2026, filed August 14, 2026 · SEC CIK 1907884

Reported value
$1.8bn
100% in companies we cover
Positions we cover
32
Largest CLDX 10.9%
Copy, a year
+24.6%
S&P 500 +14.1%
Copy Sharpe ratio
0.67
S&P 500 0.63

How copying its 13F would have done

$10.0k$20.0k 20222023202420252026 $28.2k$18.6k
CopyS&P 500 $10,000 copying Kynam Capital Management, LP's filed holdings in companies we cover from February 18, 2022, buying on the first trading day after each 13F was filed and holding until the next, against the S&P 500 (total return). Marked weekly, log scale. Before costs and taxes; misses trading within each quarter and anything 13F does not show (shorts, cash, bonds, non-US holdings).

Biggest drop −38.6% (S&P 500 −20.5%); beta 1.06; alpha +13.4% a year (t = 0.92); last 12 months +24.8% against +12.1%.

Reported value by quarter

Kynam Capital Management, LP: 13F reported value Total value of all positions in each quarter's 13F, as filed (values before 2023 were filed in thousands of dollars and are converted).
$0 $200B $400B $600B $800B Reported value, 2021-12-31: $187.1M Reported value, 2022-03-31: $307.6M Reported value, 2022-06-30: $387.6M Reported value, 2022-09-30: $473.3M Reported value, 2022-12-31: $651.9B Reported value, 2023-03-31: $773M Reported value, 2023-06-30: $652.5M Reported value, 2023-09-30: $601.6M Reported value, 2023-12-31: $883.6M Reported value, 2024-03-31: $898.9M Reported value, 2024-06-30: $955.2M Reported value, 2024-09-30: $1.3B Reported value, 2024-12-31: $1.5B Reported value, 2025-03-31: $1.2B Reported value, 2025-06-30: $928.8M Reported value, 2025-09-30: $1.3B Reported value, 2025-12-31: $1.5B Reported value, 2026-03-31: $1.6B Reported value, 2026-06-30: $1.8B 2021-12-31 2022-12-31 2023-12-31 2024-12-31 2026-06-30 $1.8B
View chart data
Period Reported value
2021-12-31 $187.1M
2022-03-31 $307.6M
2022-06-30 $387.6M
2022-09-30 $473.3M
2022-12-31 $651.9B
2023-03-31 $773M
2023-06-30 $652.5M
2023-09-30 $601.6M
2023-12-31 $883.6M
2024-03-31 $898.9M
2024-06-30 $955.2M
2024-09-30 $1.3B
2024-12-31 $1.5B
2025-03-31 $1.2B
2025-06-30 $928.8M
2025-09-30 $1.3B
2025-12-31 $1.5B
2026-03-31 $1.6B
2026-06-30 $1.8B

Latest covered holdings and moves

Covered holdings as of June 30, 2026.

CompanyShare of portfolioValueSharesChange in shares
CLDXCelldex Therapeutics, Inc.10.95%$198.1m5.32M−8.9% Reduced
SNDXSyndax Pharmaceuticals Inc9.73%$176.0m8.05M0.0%
PCVXVaxcyte, Inc.9.39%$169.9m2.92M0.0%
COGTCogent Biosciences, Inc.7.84%$141.9m3.67M−9.2% Reduced
VERAVera Therapeutics, Inc.6.85%$124.0m2.89M−15.0% Reduced
VRDNViridian Therapeutics, Inc.\de6.55%$118.6m6.45M+175.6% Added
TVTXTravere Therapeutics, Inc.6.28%$113.6m2.00M+27.5% Added
BEAMBeam Therapeutics Inc.5.39%$97.5m2.84M−22.9% Reduced
URGNUrogen Pharma Ltd.4.95%$89.6m2.43M+8.3% Added
LEGNLegend Biotech Corp4.79%$86.7m3.00M+90.4% Added
CTMXCytomx Therapeutics, Inc.4.50%$81.4m21.70M+44.6% Added
RLAYRelay Therapeutics, Inc.3.41%$61.7m3.30M+131.7% Added
CGEMCullinan Therapeutics, Inc.3.13%$56.7m3.11M0.0%
MBXMBX Biosciences, Inc.2.85%$51.6m934.8K0.0%
IMCRImmunocore Holdings plc2.41%$43.7m1.38M+55.4% Added
NRIXNurix Therapeutics, Inc.1.60%$29.0m1.19M0.0%
STROSutro Biopharma, Inc.1.60%$29.0m872.6K0.0%
BCRXBiocryst Pharmaceuticals Inc1.39%$25.2m2.52M−55.6% Reduced
PHVSPharvaris N.V.1.26%$22.9m661.8K+3.3% Added
SMMTSummit Therapeutics Inc.0.97%$17.5m1.20MNew
PRLDPrelude Therapeutics Inc0.71%$12.9m2.42M+51.6% Added
INSMInsmed Inc0.59%$10.7m100.0KNew
BNRBurning Rock Biotech Ltd0.58%$10.5m1.24M+0.9% Added
GERNGeron Corp0.48%$8.8m6.84M0.0%
AMRNAmarin Corp plc\uk0.47%$8.5m533.0K+12.8% Added
ALECAlector, Inc.0.42%$7.7m3.81M+90.4% Added
PBLSParabilis Medicines, Inc.0.38%$6.8m250.0KNew
CRBUCaribou Biosciences, Inc.0.24%$4.4m2.50M0.0%
PRQRProqr Therapeutics N.V.0.16%$2.9m1.57M0.0%
CADLCandel Therapeutics, Inc.0.06%$996,43296.7K−51.6% Reduced
ENGNEngene Therapeutics Inc.0.04%$792,089457.9KNew
TRAWTraws Pharma, Inc.0.00%$71,17584.4KNew
CompanyBought (value)Shares
VRDNViridian Therapeutics, Inc.\de$75.5m4.11M
LEGNLegend Biotech Corp$41.2m1.42M
RLAYRelay Therapeutics, Inc.$35.1m1.88M
CTMXCytomx Therapeutics, Inc.$25.1m6.69M
TVTXTravere Therapeutics, Inc.$24.5m431.0K
SMMTSummit Therapeutics Inc.$17.5m1.20M
IMCRImmunocore Holdings plc$15.6m490.1K
INSMInsmed Inc$10.7m100.0K
URGNUrogen Pharma Ltd.$6.9m186.8K
PBLSParabilis Medicines, Inc.$6.8m250.0K
PRLDPrelude Therapeutics Inc$4.4m822.5K
ALECAlector, Inc.$3.6m1.81M
AMRNAmarin Corp plc\uk$965,96460.6K
ENGNEngene Therapeutics Inc.$792,089457.9K
PHVSPharvaris N.V.$740,01221.4K

Change in shares on the previous quarter's 13F, valued at this quarter's reported price.

CompanySold (value)Shares
BCRXBiocryst Pharmaceuticals Inc−$31.6m−3.16M
BEAMBeam Therapeutics Inc.−$28.9m−841.4K
VERAVera Therapeutics, Inc.−$21.8m−508.2K
CLDXCelldex Therapeutics, Inc.−$19.3m−517.7K
EVMNEvommune, Inc.−$14.4m−625.5K
COGTCogent Biosciences, Inc.−$14.3m−370.2K
DSGNDesign Therapeutics, Inc.−$8.3m−784.6K
CLYMClimb Bio, Inc.−$6.9m−1.00M
BHVNBiohaven Ltd.−$5.9m−702.9K
CADLCandel Therapeutics, Inc.−$1.1m−103.3K

Change in shares on the previous quarter's 13F, valued at this quarter's reported price.

CompanyValue last quarterShares
EVMNEvommune, Inc.$14.4m625.5K
DSGNDesign Therapeutics, Inc.$8.3m784.6K
CLYMClimb Bio, Inc.$6.9m1.00M
BHVNBiohaven Ltd.$5.9m702.9K
  • Health Care100.0%

Share of the value held in companies we cover, by sector.

PeriodCopy, a yearS&P 500SharpeS&P 500Biggest dropBeta
Whole backtestFebruary 18, 2022 to November 2, 2026+24.6%+14.1%0.670.63−38.6%1.06
Last three yearsNovember 3, 2023 to November 2, 2026+42.1%+21.8%1.041.16−38.6%1.27
Last yearNovember 7, 2025 to November 2, 2026+33.5%+14.2%0.860.84−23.7%0.97

From SEC Form 13F data sets. A 13F lists long positions in US-listed shares at the quarter's end, filed up to 45 days later; it does not show shorts, cash, bonds, non-US holdings or trades within the quarter. Positions in companies outside our coverage are not listed here. Research, not investment advice.